258 related articles for article (PubMed ID: 26431041)
21. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
24. Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.
Kader AK; Liss MA; Trottier G; Kim ST; Sun J; Zheng SL; Chadwick K; Lockwood G; Xu J; Fleshner NE
Urology; 2015 Jan; 85(1):165-70. PubMed ID: 25530379
[TBL] [Abstract][Full Text] [Related]
25. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
26. Search for genetic factor association with cancer-free prostate-specific antigen level elevation on the basis of a genome-wide association study in the Korean population.
Choe EK; Lee Y; Cho JY; Choi SH; Park B; Lee JE; Cho EY
Eur J Cancer Prev; 2018 Sep; 27(5):453-460. PubMed ID: 28471803
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
28. The presence of prostate cancer at biopsy is predicted by a number of genetic variants.
Kashyap A; Kluźniak W; Wokołorczyk D; Gołąb A; Sikorski A; Słojewski M; Gliniewicz B; Świtała J; Borkowski T; Borkowski A; Antczak A; Wojnar Ł; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała P; Piotrowski K; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dębniak T; Górski B; Masojć B; van de Wetering T; Menkiszak J; Akbari MR; Lubiński J; Narod SA; Cybulski C;
Int J Cancer; 2014 Mar; 134(5):1139-46. PubMed ID: 24037955
[TBL] [Abstract][Full Text] [Related]
29. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.
Wiklund F; Zheng SL; Sun J; Adami HO; Lilja H; Hsu FC; Stattin P; Adolfsson J; Cramer SD; Duggan D; Carpten JD; Chang BL; Isaacs WB; Grönberg H; Xu J
Prostate; 2009 Mar; 69(4):419-27. PubMed ID: 19116992
[TBL] [Abstract][Full Text] [Related]
30. Genetic variants at 1q32.1, 10q11.2 and 19q13.41 are associated with prostate-specific antigen for prostate cancer screening in two Korean population-based cohort studies.
Kim S; Shin C; Jee SH
Gene; 2015 Feb; 556(2):199-205. PubMed ID: 25434496
[TBL] [Abstract][Full Text] [Related]
31. Re-examining Prostate-specific Antigen (PSA) Density: Defining the Optimal PSA Range and Patients for Using PSA Density to Predict Prostate Cancer Using Extended Template Biopsy.
Jue JS; Barboza MP; Prakash NS; Venkatramani V; Sinha VR; Pavan N; Nahar B; Kanabur P; Ahdoot M; Dong Y; Satyanarayana R; Parekh DJ; Punnen S
Urology; 2017 Jul; 105():123-128. PubMed ID: 28431993
[TBL] [Abstract][Full Text] [Related]
32. Genome-wide association study identified novel genetic variant on SLC45A3 gene associated with serum levels prostate-specific antigen (PSA) in a Chinese population.
Sun J; Tao S; Gao Y; Peng T; Tan A; Zhang H; Yang X; Qin X; Hu Y; Feng J; Kim ST; Lin X; Wu Y; Zhang J; Li Z; Li L; Mo L; Liang Z; Shi D; Huang Z; Huang X; Liu M; Liu Q; Zhang S; Lilly Zheng S; Xu J; Mo Z
Hum Genet; 2013 Apr; 132(4):423-9. PubMed ID: 23269536
[TBL] [Abstract][Full Text] [Related]
33. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.
Grossfeld GD; Latini DM; Lubeck DP; Mehta SS; Carroll PR
J Urol; 2003 Jan; 169(1):157-63. PubMed ID: 12478126
[TBL] [Abstract][Full Text] [Related]
34. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer.
Nordström T; Akre O; Aly M; Grönberg H; Eklund M
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):57-63. PubMed ID: 29259293
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
37. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
[TBL] [Abstract][Full Text] [Related]
38. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes.
Xu J; Meyers DA; Sterling DA; Zheng SL; Catalona WJ; Cramer SD; Bleecker ER; Ohar J
Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):664-9. PubMed ID: 12101115
[TBL] [Abstract][Full Text] [Related]
39. Measurement of serum isoform [-2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10 ng/ml.
Furuya K; Kawahara T; Narahara M; Tokita T; Fukui S; Imano M; Mitome T; Ito Y; Izumi K; Osaka K; Yokomizo Y; Hayashi N; Hasumi H; Nawata S; Kawano T; Yao M; Uemura H
Scand J Urol; 2017 Aug; 51(4):251-257. PubMed ID: 28351193
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
